Pharming Group (NASDAQ:PHAR) Earns Outperform Rating from Oppenheimer

Pharming Group (NASDAQ:PHAR)‘s stock had its “outperform” rating reaffirmed by analysts at Oppenheimer in a note issued to investors on Friday,Benzinga reports. They presently have a $41.00 target price on the stock, down from their prior target price of $42.00. Oppenheimer’s price objective points to a potential upside of 182.56% from the company’s previous close.

Several other analysts have also recently weighed in on the stock. Wall Street Zen raised shares of Pharming Group to a “strong-buy” rating in a research note on Saturday, December 27th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pharming Group in a research report on Monday, December 22nd. HC Wainwright set a $37.00 price objective on Pharming Group and gave the company a “buy” rating in a report on Thursday. Finally, Zacks Research lowered Pharming Group from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 1st. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $39.00.

Pharming Group Stock Down 4.2%

NASDAQ PHAR opened at $14.51 on Friday. The business’s fifty day simple moving average is $17.21 and its 200-day simple moving average is $16.07. The company has a quick ratio of 2.39, a current ratio of 3.16 and a debt-to-equity ratio of 0.35. The firm has a market cap of $1.02 billion, a PE ratio of 1,451.00 and a beta of 0.04. Pharming Group has a 52 week low of $7.50 and a 52 week high of $21.34.

Pharming Group (NASDAQ:PHAR) last announced its quarterly earnings data on Thursday, March 12th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.08). Pharming Group had a net margin of 0.71% and a return on equity of 1.12%. The firm had revenue of $106.50 million during the quarter, compared to analysts’ expectations of $111.76 million. As a group, equities analysts anticipate that Pharming Group will post -0.2 earnings per share for the current year.

Institutional Trading of Pharming Group

Several institutional investors have recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC purchased a new stake in Pharming Group in the second quarter valued at approximately $32,000. SmartHarvest Portfolios LLC purchased a new position in shares of Pharming Group during the fourth quarter worth $224,000. Millennium Management LLC purchased a new position in shares of Pharming Group during the fourth quarter worth $360,000. Finally, NewEdge Advisors LLC grew its stake in shares of Pharming Group by 11,310.3% in the fourth quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock valued at $510,000 after buying an additional 28,615 shares in the last quarter. Institutional investors and hedge funds own 0.03% of the company’s stock.

Key Headlines Impacting Pharming Group

Here are the key news stories impacting Pharming Group this week:

• Positive Sentiment: Company set a 2026 revenue target of $405M–$425M, citing growth from Joenja and RUCONEST as primary drivers — this provides clear growth levers for next year and supports upside if execution meets targets. Pharming outlines $405M–$425M 2026 revenue target
• Positive Sentiment: Company reported full-year and Q4 2025 revenue growth and positive cash flow and reaffirmed 2026 guidance — fundamentals showing improving cash generation can reduce funding risk and support valuation. Pharming Group reports fourth quarter and full year 2025 financial results
• Positive Sentiment: Oppenheimer reiterated an “Outperform” rating with a $41 price target (slightly trimmed), signaling continued bullish analyst conviction and implying substantial upside from current levels. Oppenheimer reaffirms outperform on PHAR
• Neutral Sentiment: HC Wainwright maintains a Buy rating and $37 target but lowered FY2026 EPS from $0.49 to $0.35 — the firm still expects material 2026 profitability, but the cut shows some model uncertainty around timing and magnitude of margin expansion. HC Wainwright updates estimates for PHAR
• Negative Sentiment: Q4 results missed expectations: revenue $106.5M vs. analyst ~$111.8M and EPS $0.07 vs. $0.15 expected — the quarter’s misses likely triggered the intraday sell-off despite upbeat guidance. Pharming Q4 2025 press release

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.